Find disease awareness content and relevant supporting materials
MicroRNA as a diagnostic biomarker in childhood acute lymphoblastic leukemia; systematic review, meta-analysis and recommendations.
Several studies detected abnormal mi-RNAs expression levels in childhood Acute Lymphoblastic Leukemia (ALL) with potential diagnostic value. We conducted a systematic search on certain microRNAs in childhood ALL.
Phase III study of Blincyto in acute lymphoblastic leukemia published in Journal of the American Medical Association.- Amgen
Amgen announced that data from a multicenter, randomized Phase III study evaluating the efficacy, safety and tolerability of Blincyto (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) were published in The Journal of the American Medical Association (JAMA).